Cannabis Use For Managing Symptoms and Side Effects
Learn what the research says about cannabis use for people living with MBC
FDA Approves MARGENZA
On December 16, 2020, the FDA approved margetuximab-cmkb (MARGENZA®) in combination with chemotherapy, for treating metastatic HER2-positive breast cancer.
Warmest Wishes for 2021
With your continued support, we can make every U.S. breast cancer trial available on our clinical trial search platform and bring you the most relevant and trusted news and information to help people understand and access these trials.
Metastatic Trial Search: New & Improved
Match to new biomarkers, new sites of metastatic spread, and measurable disease. Now easier to use on a phone, laptop and desktop.
FDA Approves Keytruda®
On November 13, 2020, the FDA approved pembrolizumab (Keytruda®) in combination with chemotherapy for the treatment of patients with locally recurrent unresectable or metastatic triple-negative breast cancer (TNBC) whose tumors express PD-L1 as determined by an FDA approved test.
Living with Metastatic Breast Cancer During October
Metastatic Breast Cancer Awareness Day is a day selected to focus on MBC. Learn the experiences of living with MBC and ways how you can help.
FDA Approves PHESGO
In late June, the FDA approved PHESGO (pertuzumab/ trastuzumab/ hyaluronidase-zzxf), a treatment that can be injected under the skin, to treat metastatic and early-stage HER2 positive breast cancer. Because it is given as an injection, PHESGO can be given by a healthcare professional in your home, and takes less time than an infusion.